How Immuneering’s Journey Highlights the Biotech Markets Complexity, with CEO Ben Zeskind

Outsmarting resistance with rhythm

Immuneering CEO shares his cancer drug development strategy

Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel

New Combination Treatment Approach Studied in Pancreatic Cancer

Improving Tolerability and Quality of Life in Pancreatic Cancer Treatment with Atebimetinib

A cancer treatment modality that prioritises QoL, with Ben Zeskind

Atebimetinib Signals a Potential Shift in First-Line Pancreatic Cancer Outcomes

Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer

Atebimetinib Combo Shows Compelling 1-Year OS in First-Line Pancreatic Cancer